AllCells, LLC (Alameda, CA) will participate in an oral presentation at the American Society of Hematology (ASH) annual meeting to be held December 3-6, 2016, in San Diego, CA, on studies using hematopoietic stem cells for the treatment of hematological malignancies, cancers and other genetic blood disorders. The work, funded by the New York State Stem Cell Science Program (NYSTEM) and led by Dr. Ronald Hoffman of the Icahn School of Medicine at Mount Sinai (New York, NY), will demonstrate the ability to isolate and expand hematopoietic stem cells (HSCs) from fresh and frozen cord blood units. While utilizing its expertise in HSC manufacturing and isolation, AllCells, LLC also collaborated closely with Miltenyi Biotec GmbH (Bergisch Gladbach, Germany) in developing a protocol to isolate CD34 cells on their next generation closed GMP-compliant system, the CliniMACS Prodigy®. The work represents a major step in bringing the technology closer to the clinic, as well as contributing towards AllCells, LLC’s vision to support the development of clinical applications.
AllCells, LLC is also presenting a poster at ASH highlighting work on the utilization of cord-blood expanded stem cells for megakaryocyte and platelet production. The work is funded by an ongoing grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NHLBI-NIH) and performed in collaboration with Dr. Camelia Iancu-Rubin, Associate Professor of Medicine, Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai (New York, NY). The work capitalizes on Dr. Iancu-Rubin’s extensive knowledge on megakaryocyte biology and AllCells, LLC’s expertise in large-scale cell isolation and cryopreservation to develop a clinical product for the treatment of thrombocytopenias, and to meet the growing industry demand for platelet supply.